Format

Send to

Choose Destination
Cancer J. 2016 Mar-Apr;22(2):68-72. doi: 10.1097/PPO.0000000000000185.

Immune Checkpoint Therapy and the Search for Predictive Biomarkers.

Author information

1
From the Departments of Immunology and Genitourinary Medical Oncology, M. D. Anderson Cancer Center, Houston, TX.P.S.'s work was supported by the SU2C-CRI Dream Team Cancer Immunotherapy Grant, PCF Challenge Grant in Immunology, NCI/NIH 1-R01 CA1633793-01, and Cancer Prevention Research in Texas (grant RP120108).

Abstract

Immune checkpoint therapy has started a revolution in the field of oncology. The concept that the immune system plays a critical role in antitumor responses, which has been around for decades, has finally been proven and firmly established with elegant preclinical studies and dramatic clinical responses in patients as a result of antibodies that block inhibitory T-cell pathways. However, the clinical responses being achieved are only in a subset of patients, and more work is needed to provide a better understanding of the mechanisms that elicit tumor rejection, which will enable identification of appropriate biomarkers, reveal new targets, provide data to guide combination studies, and eventually dictate a platform that allows more patients to derive clinical benefit, including cures, with immune checkpoint therapy.

PMID:
27111900
PMCID:
PMC4847150
[Available on 2017-03-01]
DOI:
10.1097/PPO.0000000000000185
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center